Loading...
Intas Pharmaceuticals Limited — Docetaxel Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #4 for Docetaxel · $2.2M export value · DGFT Verified
Intas Pharmaceuticals Limited is the #4 Indian exporter of Docetaxel with $2.2M in export value and 44 verified shipments. Intas Pharmaceuticals Limited holds a 5.6% market share in Docetaxel exports across 9 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| MEXICO | $300.0K | 6 | 23.0% |
| AUSTRALIA | $270.3K | 8 | 20.7% |
| KOREA,REPUBLIC OF | $200.0K | 4 | 15.3% |
| SOUTH AFRICA | $124.6K | 3 | 9.6% |
| PHILIPPINES | $106.1K | 15 | 8.1% |
| REPUBLIC OF KOREA | $100.0K | 2 | 7.7% |
| UNITED STATES | $100.0K | 2 | 7.7% |
| SOUTH KOREA | $50.0K | 1 | 3.8% |
| UNITED KINGDOM | $45.7K | 1 | 3.5% |
| CANADA | $7.0K | 2 | 0.5% |
Intas Pharmaceuticals Limited exports Docetaxel to 11 countries. The largest destination is MEXICO accounting for 23.0% of Intas Pharmaceuticals Limited's Docetaxel shipments, followed by AUSTRALIA (20.7%) and KOREA,REPUBLIC OF (15.3%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | SOUTH AFRICA | $227.2K | 7 |
| TO INDUSTRIAL BANK OF KOREA | KOREA,REPUBLIC OF | $150.0K | 3 |
| INDUSTRIAL BANK OF KOREA | REPUBLIC OF KOREA | $150.0K | 3 |
| ACCORD HEALTHCARE PTY LTD | AUSTRALIA | $120.3K | 5 |
| EVERSANA LIFE SCIENCES SERVICES,LLC | UNITED STATES | $100.0K | 2 |
| ACCORD FARMA S A DE C V | MEXICO | $100.0K | 2 |
India exported $22.4M worth of Docetaxel through 2,634 shipments from 253 suppliers to 120 countries, serving 641 buyers globally. Intas Pharmaceuticals Limited contributes $2.2M to this total, accounting for 5.6% of India's Docetaxel exports. Intas Pharmaceuticals Limited ships Docetaxel to 11 countries through 17 buyers.
Intas Pharmaceuticals Limited's average Docetaxel shipment value is $50.0K per consignment, based on 44 shipments totaling $2.2M. The largest destination is MEXICO (23.0% of Intas Pharmaceuticals Limited's Docetaxel exports).
Intas Pharmaceuticals Limited ranks #4 among 253 Indian Docetaxel exporters with a 5.6% market share. The top 3 exporters are FRESENIUS KABI ONCOLOGY LIMITED ($8.4M), MYLAN LABORATORIES LIMITED ($3.5M), INTAS PHARMACEUTICALS LIMITED ($2.2M). Intas Pharmaceuticals Limited processed 44 shipments to 9 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMA DRUG&MED: TAXANIT RTU 4 ML (20 mg/ml, 4ml) TAXANIT RTU 4 ML INJECTION EACH ML CONTAINS: DOCETAXEL ANHYDROUS PH.EU | $150.0K | 3 |
| PHARMA DRUGS AND MEDI ACCORD DOCETAXEL20 | $100.0K | 2 |
| PHARMA DRUGS AND MEDI ACCORD DOCETAXEL20MG ML 1ML AS PER INV | $100.0K | 2 |
| PHARMA DRUGS AND MEDI TAXANIT RTU 4 ML 20 MG/ML 4ML TAXANIT RTU 4 ML INJECTION EACH ML CONTAINS: DOCETAXEL ANHYDROUS | $100.0K | 2 |
| PHARMA DRUGS & MEDI DOCETAXEL ACCORD 160 | $73.5K | 3 |
| PHARMACEUTICAL DRUGS AND MEDICINE-TAXTASDOCETAXEL20MG/ML 4ML 1V(AC-PHP) EACH MLCONTAINSCOLON DOCETAXEL ANHYDROUS | $59.9K | 4 |
| PHARMACEUTICAL DRUGS AND MEDICINE DOCETAXEL ACCORD 80MG 4 ML AS PER INVOICE | $50.0K | 1 |
| PHR DRUGS&MEDI DOCETAXEL INJECTION USP 2 |
What Intas Pharmaceuticals Limited must comply with to export Docetaxel to its top destination countries
Approval Process
Generic registration under Mexican health law. NOM standards apply.
Timeline: 12–18 months
GMP & Export Requirements
Mexican GMP (NOM-059-SSA1); COFEPRIS overseas inspection or PIC/S certificate
Sanitary Import Permit from COFEPRIS; import licence via SAT
Note: COFEPRIS participates in PIC/S, easing recognition of PIC/S certificates from Indian authorities.
Approval Process
Registration on Australian Register of Therapeutic Goods (ARTG). Bioequivalence and quality data per TGA guidelines.
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED | $8.4M | 356 | 21 | $23.5K |
| 2 | MYLAN LABORATORIES LIMITED | $3.5M | 69 | 1 | $50.0K |
| 4 | INTAS PHARMACEUTICALS LIMITED ★ | $2.2M | 44 | 9 | $50.0K |
| 8 | EUGIA PHARMA SPECIALITIES LIMITED | $1.1M | 88 | 2 |
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 530 | 20.1% |
| DELHI AIR | 416 | 15.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 379 | 14.4% |
| SAHAR AIR | 372 | 14.1% |
| Bombay Air | 132 | 5.0% |
| Delhi Air | 90 | 3.4% |
| HYDERABAD AIR | 79 | 3.0% |
| HYDERABAD ACC (INHYD4) | 54 | 2.1% |
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Docetaxel, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Docetaxel — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Docetaxel exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
| TO THE ORDER . | AUSTRALIA | $100.0K | 2 |
| ACCORD HEALTHCARE LTD (PHILIPPINES) | PHILIPPINES | $69.0K | 7 |
| ACCORD HEALTHCARE C/O QESTMED (PTY) | SOUTH AFRICA | $50.0K | 1 |
| TO INDUSTRIAL BANK | SOUTH KOREA | $50.0K | 1 |
Intas Pharmaceuticals Limited supplies Docetaxel to 17 buyers globally. The largest buyer is TO THE ORDER (SOUTH AFRICA), followed by TO INDUSTRIAL BANK OF KOREA (KOREA,REPUBLIC OF) and INDUSTRIAL BANK OF KOREA (REPUBLIC OF KOREA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| $50.0K |
| 1 |
| PHA.DRU & MEDI, DOCETAXEL INJECTION 20 m | $50.0K | 1 |
| PHARMACEUTICAL DRUGS AND MEDICINE : ACCORD DOCETAXEL20MG/ML-4ML 1X1V S.KOREA Each mL contains Docetaxel anhydrous Ph. | $50.0K | 1 |
Intas Pharmaceuticals Limited exports 28 distinct Docetaxel formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMA DRUG&MED: TAXANIT RTU 4 ML (20 mg/ml, 4ml) TAXANIT RT with 3 shipments worth $150.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Timeline: 10–14 months
GMP & Export Requirements
TGA GMP clearance; PIC/S-aligned inspection. PIC/S certificate from India may expedite.
TGA sponsor licence for Australian importer; GMP clearance per manufacturing site
Note: TGA participates in PIC/S mutual recognition.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| $12.6K |
| 9 | NV REMEDIES PRIVATE LIMITED | $959.1K | 27 | 4 | $35.5K |
Intas Pharmaceuticals Limited ranks #4 among 253 Indian Docetaxel exporters. Average shipment value of $50.0K compared to the market average of $88.6K. The closest competitors by value are FRESENIUS KABI ONCOLOGY LIMITED and MYLAN LABORATORIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 120+ countries, 641+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Docetaxel. For current shipment-level data, contact TransData Nexus.